Nephros (NASDAQ:NEPH) Announces Earnings Results

Nephros (NASDAQ:NEPH) issued its earnings results on Thursday. The company reported $0.06 EPS for the quarter, Zacks reports. Nephros had a net margin of 8.38% and a return on equity of 11.03%. The company had revenue of $6.02 million for the quarter, compared to analyst estimates of $4.99 million.

Here are the key takeaways from Nephros’ conference call:

• Record revenue and broad-based growth: Second-quarter revenue reached $6.0 million, up 36% year over year and 15% sequentially. Programmatic product revenue rose 27%, service revenue nearly tripled, and growth was driven largely by increased sales and services within existing customer sites.
• Profitability improved substantially: Net income increased more than 400% to approximately $1.2 million, while adjusted EBITDA rose 260% to $1.3 million. The company ended the quarter with $4.7 million in cash and no debt.
• Reported margins benefited from a one-time tariff refund: The 67% quarterly gross margin included approximately $600,000 of tariff refunds, about $500,000 of which related to inventory sold in prior periods. Management expects tariff policy, currency movements, shipping costs, and the growing mix of lower-margin services and commercial products to continue pressuring underlying margins.
• New products remain an emerging opportunity rather than a current growth driver: PFAS, microplastics, and nanoplastics offerings have not yet gained significant traction and may require additional education, trials, and regulatory momentum. Education initiatives are currently used to drive product adoption and are not being monetized directly.
• Cash generation weakened: Operating cash flow fell to $681,000 in the second quarter from $994,000 a year earlier, while first-half operations used $990,000 as accounts receivable and inventory increased.

Nephros Price Performance

NEPH traded up $0.62 during trading on Friday, reaching $4.21. 67,358 shares of the stock were exchanged, compared to its average volume of 10,920. The company has a market capitalization of $45.72 million, a price-to-earnings ratio of 38.27 and a beta of 1.51. Nephros has a 1 year low of $2.66 and a 1 year high of $6.42. The business’s 50 day moving average price is $3.48 and its two-hundred day moving average price is $3.53.

Analysts Set New Price Targets

Several brokerages recently commented on NEPH. Northland Securities started coverage on shares of Nephros in a research note on Friday, July 17th. They issued a “market perform” rating and a $4.00 price objective for the company. Zacks Research upgraded shares of Nephros to a “hold” rating in a research report on Monday, July 20th. Finally, Weiss Ratings raised shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 3rd. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $4.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd boosted its position in shares of Nephros by 48.5% in the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after buying an additional 7,062 shares in the last quarter. Quadrature Capital Ltd purchased a new position in Nephros during the 4th quarter valued at about $112,000. Kestra Advisory Services LLC purchased a new position in Nephros during the 4th quarter valued at about $29,000. Marshall Wace LLP acquired a new position in Nephros during the fourth quarter worth about $107,000. Finally, Essex Investment Management Co. LLC raised its position in Nephros by 57.1% during the fourth quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock worth $190,000 after acquiring an additional 14,162 shares during the last quarter. Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.